???????? ???????????? ????????????-???? ???????????????????? ???????????????????????????????????? ??

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
The future of medicine is shifting — GLP-1 drugs like Ozempic and Wegovy are disrupting traditional oncology pipelines. With over 13 obesity-related cancers and real-world evidence showing reduced cancer risk, GLP-1 receptor agonists are no longer just weight-loss drugs — they’re the future of cancer prevention.

In this video, we break down:

The market forecast for GLP-1 and cancer therapies from 2024 to 2029

How obesity causes cancer at the molecular level

Real-world evidence linking GLP-1 therapies to reduced cancer risk

Why pharma investment is shifting from oncology to obesity

Don't miss this breakdown of the most important pivot in healthcare investment and biotech strategy.

???? Subscribe for updates on biotech, obesity treatment, GLP-1 trends, and healthcare innovation.

#GLP1 #Ozempic #Wegovy #CancerPrevention #ObesityCure #BiotechNews #HealthcareInnovation #MetabolicHealth #FutureOfMedicine #RWE #PharmaTrends #ObesityEpidemic #GLP1Drugs #WeightLossDrugs #OncologyPipeline #HealthTech #Lilly #NovoNordisk #PrecisionMedicine
Category
Oncology
Be the first to comment

Up Next